跳至主要内容
临床试验/NCT01343420
NCT01343420已完成不适用

Dog Hair Evaluation Potency by Prick Skin Testing

National Jewish Health2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2010年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
15
试验地点
2
主要终点
End-point dilution giving a positive prick skin test in dog allergic subjects.

研究概览

简要总结

Liquid allergen extracts contain proteins, such as (but not limited to) tree, weed, cat, cockroach, and nuts, and are used to identify allergies by observing the body's reaction to the introduction of extract underneath the skin. There are a few dog allergen extracts commercially available in the US for allergy testing; however, none of these products are standardized, meaning they are not required to be the same strength. Because some extracts are not as potent (strong) as others, it's possible that some patients' allergies are misdiagnosed. Typically, the most potent (strong), but safe extract should be used so that allergic patients are correctly diagnosed.

The purpose of this study is to compare the safety and potency of an investigational (not approved for use by the United States Food and Drug Administration [FDA]) dog allergen extract with two commercially available dog extracts, which are of differing potencies.

详细描述

This study is designed to assess the potency of a modified dog hair and dander extract in comparison with the two commercially available dog hair and dander extracts. This is a pilot study to estimate a target strength of dog extract in order to proceed to further studies.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must sign informed consent before completing any study procedure.
  • Age 18 years and ≤60 years.
  • Dog-sensitized patients as indicated by a mean wheal > 5 mm with the AP dog extract.
  • Females of child-bearing potential must have a negative pregnancy test the day of skin testing.
  • Patients who are able to understand the information given and be compliant with the protocol.

排除标准

  • Asthma requiring treatment with medications other than beta-2 inhaled agonists and montelukast inhibitors.
  • Patients with a history of asthma or wheezing with an FEV1 <80%.
  • Subjects who have taken an ocular or nasal antihistamine within 5 days prior to the procedures.
  • Patients who have received any desensitization for dog allergen in the past 5 years.
  • Patients with any past or current clinically significant condition that may affect the patient's participation or the outcome of the study to the discretion of the investigator. These include, but are not limited to, anaphylaxis with cardio-respiratory symptoms, chronic urticaria and angioedema unless related to dog exposure, severe atopic dermatitis, malignancy, cardiovascular, hepatic, renal, hematological, neurological, immunological, and endocrine disease.
  • Subjects taking beta blockers, ace inhibitors, continuous systemic corticotherapy, immunosuppressive drugs or monoamine oxidase inhibitors.
  • Use of H1 antagonists, tricyclic antidepressants and phenothiazines within 5 days prior to the testing.

结局指标

主要结局

End-point dilution giving a positive prick skin test in dog allergic subjects.

时间窗: Study Completion

The concentration of each allergen extract which produced a 5 mm wheal for each subject will be calculated. From this, the relative potency of each extract will be calculated.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验